Compare PNFP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | DVA |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 14.9B |
| IPO Year | 2025 | 2003 |
| Metric | PNFP | DVA |
|---|---|---|
| Price | $93.85 | $175.97 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | $113.31 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 789.4K | 561.0K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ 35.40 | N/A |
| EPS | 2.96 | ★ 6.86 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $160.52 | $3.85 |
| Revenue Next Year | $9.24 | $3.07 |
| P/E Ratio | $31.20 | ★ $25.46 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $81.08 | $101.00 |
| 52 Week High | $110.33 | $247.49 |
| Indicator | PNFP | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.18 | 38.56 |
| Support Level | $81.76 | $173.99 |
| Resistance Level | $100.81 | $202.63 |
| Average True Range (ATR) | 2.29 | 5.17 |
| MACD | -0.41 | -0.20 |
| Stochastic Oscillator | 2.73 | 2.68 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.